Why the study?
Do natriuretic peptides (ANP, BNP, CNP) predict mortality and need for heart transplant in patients with Chagas' disease?
Do natriuretic peptides (ANP, BNP, CNP) predict mortality and need for heart transplant in patients with Chagas' disease?
ANP and BNP are valuable biomarkers for identifying asymptomatic Chagas' disease patients and predicting adverse clinical outcomes such as mortality and heart transplant.
May aid prognostication in Chagas cardiomyopathy; leaves open prospective validation before clinical use.
To determine the diagnostic and prognostic value of natriuretic peptides in patients with Chagas' disease (CD), the authors first measured atrial (ANP), B-type (BNP), and C-type natriuretic peptide (CNP) and compared their diagnostic and prognostic capacity with that in other dilated cardiomyopathies (DCM). The CD and DCM patients were subdivided according to their New York Heart Association (NYHA) classification. Circulating ANP and more pronounced BNP, but not CNP, were increased in CD and DCM patients in relation to NYHA class. Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction. All 3 natriuretic peptides were correlated with echocardiographic parameters in CD patients. While ANP and BNP have high predictive value for mortality and necessity for heart transplant in CD, CNP can not predict them. Thus, ANP and BNP rather than CNP could be used as valuable molecular markers to identify asymptomatic CD patients for early therapy and predict clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Moreira et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: